WilliamG.WierdaMD

Oncology • Houston, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Wierda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wierda's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-3753
Is this information wrong?

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Duke University HospitalResidency, Internal Medicine, 1993 - 1996
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1993

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2002 - 2025
CA State Medical License 1996 - 2025
OK State Medical License 2020 - 2021
NC State Medical License 1993 - 1999
American Board of Internal Medicine Medical Oncology

Clinical Trials

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years Start of enrollment: 2005 Mar 14
Completed
Phase 2
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL Start of enrollment: 2004 Nov 01
Completed
Phase 1, Phase 2
CFAR Study in Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2005 Jun 01
Completed
Phase 2
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
Unknown status
Phase 2
8-Chloro-Adenosine in Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jun 01
Completed
Phase 1
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Aug 13
Completed
Phase 2
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) Start of enrollment: 2006 Jun 01
Completed
Phase 1
A Phase I Extension Trial of Repeated Infusions of ISF35 Start of enrollment: 2007 May 01
Completed
Phase 1
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2002 Dec 01
Completed
Phase 2
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Apr 19
Completed
Phase 1, Phase 2
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Nov 03
Completed
Phase 2
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2011 Mar 01
Completed
Phase 2
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Start of enrollment: 2011 Aug 22
Terminated
Phase 2
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy Start of enrollment: 2011 Jul 06
Active, not recruiting
Phase 2
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2015 Jan 01
Withdrawn
Phase 1
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2015 Aug 21
Terminated
Phase 2
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia Start of enrollment: 2017 Aug 04
Terminated
Phase 1
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL Start of enrollment: 2019 Jan 25
Completed
Phase 1
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor Start of enrollment: 2019 Jun 18
Withdrawn
Phase 1
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2020 Jul 29
Recruiting
Phase 2
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies Start of enrollment: 2016 Oct 01
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
William G Wierda, Jennifer Brown, Jeremy S Abramson, Farrukh Awan, Syed F Bilgrami, Greg Bociek, Danielle Brander, Matthew Cortese, Larry Cripe, Randall S Davis, Herbe...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 1
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
Adam S Kittai, David Bond, Ying Huang, Seema A Bhat, Emily Blyth, John C Byrd, Julio C Chavez, Matthew S Davids, Jamie P Dela Cruz, Mark R Dowling, Caitlyn Duffy, Carr...> ;Journal of Clinical Oncology. 2024 Mar 29
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Paul Joseph Hampel, Kerry A Rogers, Wei Ding, Saad S Kenderian, Sameer A Parikh, Mahesh Swaminathan, Erin M Parry, Jan A Burger, Matthew S Davids, Alessandra Ferrajoli...> ;Blood Advances. 2024 Mar 27
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Short, N., Jabbour, E., Jain, N., Senapati, J., Nasr, L., Haddad, F., Li, Z., Hsiao, Y., Yang, J., Pemmaraju, N., Ohanian, M., Wierda, W., Montalban-Bravo, G., Borthak...> ;Blood Advances. 2024 Feb 27
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Stephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, Matthew S Davids, Barbara Eichhorst, Michael Hallek, Peter Hillmen, Christof Schneider, Johannes Schetelig, Sebas...> ;Blood Advances. 2024 Apr 23
3 citations
ZNF683 marks a CD8T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome.
Parry, E., Lemvigh, C., Deng, S., Dangle, N., Ruthen, N., Knisbacher, B., Broséus, J., Hergalant, S., Guièze, R., Li, S., Zhang, W., Johnson, C., Long, J., Yin, S., We...> ;Cancer Cell. 2023 Oct 9
Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations.
Panpan Liu, Kefeng Wang, Jianan Li, Marcia A Ogasawara, Zhongjun Xia, William G Wierda, Michael J Keating, Yiqing Li, Peng Huang> ;Haematologica. 2024 Feb 1
5 citations
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Philip A Thompson, Alexandre Bazinet, William G Wierda, Constantine S Tam, Susan M O'Brien, Satabdi Saha, Christine B Peterson, William Plunkett, Michael J Keating> ;Blood. 2023 Nov 23
1 citations
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results.
Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, William Wierda, Naval Daver, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Nov 1
2 citations
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with bre...
Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzac...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
5 citations
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Barr, P. M., Barr, P. M., John N Allan, Ian W Flinn, Tanya Siddiqi, Paolo Ghia, Constantine S Tam, Thomas J Kipps, Paul M Barr, Anna Elinder Camburn, Alessandra Tedesc...> ;Clinical Cancer Research. 2023 Jul 14
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
Laura M Roccograndi, Alexandra R Lovell, Alessandra Ferrajoli, Philip A Thompson, Jan A Burger, William G Wierda, Nitin Jain, Caitlin R Rausch> ;Leukemia & Lymphoma. 2023 Sep 1
17 citations
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Tanya Siddiqi, David G Maloney, Saad S Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N Shah, Rajneesh Nath, Bita Fakhri, Deb...> ;Lancet. 2023 Aug 19
17 citations
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell...
Elias Jabbour, Nicholas J Short, Jayastu Senapati, Nitin Jain, Xuelin Huang, Naval Daver, Courtney D DiNardo, Naveen Pemmaraju, William Wierda, Guillermo Garcia-Manero...> ;The Lancet. Haematology. 2023 Jun 1
2 citations
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
Philip A Thompson, Michael J Keating, Alessandra Ferrajoli, Nitin Jain, Christine B Peterson, Naveen Garg, Sa A Wang, Jeffrey L Jorgensen, Tapan M Kadia, Prithviraj Bo...> ;Leukemia. 2023 Jul 1
2 citations
Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors.
Chia-Yu Chiu, Sairah Ahmed, Sheeba K Thomas, Lan Sun Wang, Khalis Mustafayev, Luis E Fayad, William G Wierda, Fareed Khawaja, Harrys A Torres> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Aug 1
2 citations
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
Max J Gordon, Jade E Jones, Binsah George, Christine Peterson, Jan A Burger, Nitin Jain, Michael Keating, William G Wierda, Jean-Bernard Durand, Alessandra Ferrajoli> ;Cancer. 2023 Jul 15
Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from A...
Fieke W Hoff, Ti'ara L Griffen, Brandon D Brown, Terzah M Horton, Jan Burger, William Wierda, Stefan E Hubner, Yihua Qiu, Steven M Kornblau> ;International Journal of Molecular Sciences. 2023 Mar 13
Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia.
Ti'ara L Griffen, Fieke W Hoff, Yihua Qiu, Jan Burger, William Wierda, Steven M Kornblau> ;International Journal of Molecular Sciences. 2023 Mar 13
8 citations
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
Alexandre Bazinet, Tapan Kadia, Nicholas J Short, Gautam Borthakur, Sa A Wang, Wei Wang, Sanam Loghavi, Jeffrey Jorgensen, Keyur Patel, Courtney DiNardo, Naval Daver, ...> ;Blood Advances. 2023 Jul 11
1 citations
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant.
Siba El Hussein, L Jeffrey Medeiros, Stephen K Gruschkus, Peng Wei, Ellen Schlette, Hong Fang, Fatima Zahra Jelloul, Wei Wang, Warren Fiskus, Rashmi Kanagal-Shamanna, ...> ;Virchows Archiv. 2023 Jun 1
1 citations
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.
Siba El Hussein, L Jeffrey Medeiros, Kirill A Lyapichev, Hong Fang, Fatima Zahra Jelloul, Warren Fiskus, Jiansong Chen, Peng Wei, Ellen Schlette, Jie Xu, Shaoying Li, ...> ;Pathology. 2023 Jun 1
22 citations
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.
Erin M Parry, Ignaty Leshchiner, Romain Guièze, Connor Johnson, Eugen Tausch, Sameer A Parikh, Camilla Lemvigh, Julien Broséus, Sébastien Hergalant, Conor Messer, Fili...> ;Nature Medicine. 2023 Jan 1
14 citations
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
Hagop Kantarjian, Nicholas J Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Fadi G Haddad, Issa Khouri, Courtney D DiNardo, Naveen Pemmaraju, William Wierda, Guillermo ...> ;American Journal of Hematology. 2023 Mar 1
17 citations
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an ...
Bijal D Shah, Armin Ghobadi, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Ryan D Cassaday, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzachanis, Kr...> ;Journal of Hematology & Oncology. 2022 Dec 10
Join now to see all

Journal Articles

A Pilot Study of Lower Doses of Ibrutinib in Patients with Chronic Lymphocytic Leukemia
Nitin Jain, Michael J Keating, Varsha Gandhi, William G Wierda, Blood
Evaluation of 230 Patients with relapsed/refractory Deletion 17p Chronic Lymphocytic Leukaemia Treated with Ibrutinib from 3 Clinical Trials
Steven Coutre, Richard R Furman, William G Wierda, Nyla A Heerema, Alvina D Chu, Jeffrey Jones, John C Byrd, British Journal of Haematology
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Jeffrey A Jones, William Wierda, Clinical Cancer Research

Abstracts/Posters

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
T Cell Determinants of Response and Resistance to PD-1 Blockade in RichterÍs Transformation
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of t...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocy...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Authored Content

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17pOctober 2017
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017

Press Mentions

$BTK Degrader Shows Potential for Treating Refractory CLL and SLL$
BTK Degrader Shows Potential for Treating Refractory CLL and SLLFebruary 8th, 2023
Mapping Genetic Evolution from CLL to Richter’s SyndromeJanuary 10th, 2023
Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
Join now to see all